- Home
- ADPT vs ALRM Comparison
ADPT vs ALRM Comparison
Compare ADPT & ALRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADPT | ALRM |
|---|---|---|
| Founded | 2009 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ADPT | ALRM |
|---|---|---|
| Price | $14.91 | $49.70 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 4 |
| Target Price | $17.78 | ★ $57.00 |
| AVG Volume (30 Days) | ★ 1.6M | 453.5K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | 7.42 |
| EPS | N/A | ★ 2.46 |
| Revenue | $276,976,000.00 | ★ $1,011,187,000.00 |
| Revenue This Year | $3.98 | $7.00 |
| Revenue Next Year | $22.72 | $4.53 |
| P/E Ratio | ★ N/A | $20.38 |
| Revenue Growth | ★ 54.77 | 7.59 |
| 52 Week Low | $6.26 | $43.00 |
| 52 Week High | $20.76 | $59.98 |
Technical Indicators
Market Signals| Indicator | ADPT | ALRM |
|---|---|---|
| Relative Strength Index (RSI) | 36.46 | 58.98 |
| Support Level | $12.32 | $46.43 |
| Resistance Level | $17.91 | $52.86 |
| Average True Range (ATR) | 0.74 | 1.79 |
| MACD | -0.01 | 0.63 |
| Stochastic Oscillator | 3.89 | 91.67 |
Price Performance
Historical ComparisonAbout ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About ALRM Alarm.com Holdings Inc.
Alarm.com Holdings Inc has a cloud-based platform that offers an expansive suite of IoT solutions addressing world-wide opportunities in the residential, multi-family, small business and enterprise commercial markets. It has two reportable segments: Alarm.com & Other. The Alarm.com segment represents the cloud-based Software platforms for intelligently connected property & related solutions. The other segment is focused on researching, developing & offering residential & commercial automation solutions & energy management products & services in adjacent markets. The majority of revenue is from the Alarm.com segment. The platform allows home & business owners to secure their properties and automate & control an array of connected devices.